Table 2.
Observed and expected EC rates in BRCA1/2 mutation carriers compared with the Dutch country-specific incidence rates
| EC subgroups | BRCA1/2 carriers | Dutch population | SIR (95% CI) | Pa |
|---|---|---|---|---|
| Observed | Expected | |||
| All ECs | 58 | 20.53 | 2.83 (2.18 to 3.65) | <.001 |
| BRCA1 | 44 | 12.53 | 3.51 (2.61 to 4.72) | <.001 |
| BRCA2 | 14 | 8.23 | 1.70 (1.01 to 2.87) | .04 |
| Endometrioid | 35 | 16.85 | 2.08 (1.49 to 2.89) | <.001 |
| BRCA1 | 27 | 10.27 | 2.63 (1.80 to 3.83) | <.001 |
| BRCA2 | 8 | 6.77 | 1.18 (0.59 to 2.36) | .37 |
| Serous-like | 19 | 1.95 | 9.77 (6.23 to 15.31) | <.001 |
| BRCA1 | 15 | 1.19 | 12.64 (7.62 to 20.96) | <.001 |
| BRCA2 | 4 | 0.78 | 5.11 (1.92 to 13.63) | .01 |
| Sarcoma | 3 | 1.3 | 2.30 (0.74 to 7.14) | .14 |
| BRCA1 | 1 | 0.81 | 1.24 (0.17 to 8.78) | .55 |
| BRCA2 | 2 | 0.51 | 3.95 (0.99 to 15.81) | .09 |
| Clear cell | 1 | 0.29 | 3.40 (0.48 to 24.11) | .25 |
| BRCA1 | 1 | 0.18 | 5.58 (0.79 to 39.65) | .16 |
| BRCA2 | 0 | 0.12 | NA | NA |
a
P values were estimated assuming a Poisson distribution. CI = confidence interval; EC = endometrial cancer; NA = not applicable; SIR = standardized incidence ratio.